Back
HLS
Healius Limited
🇦🇺 ASX
💰 HIGH DIVIDEND
🌳 ENVIRONMENTAL
🩺 HEALTH CARE
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
-15.85%
Annual Growth
5 years average annual capital growth
💰
35.76%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
31
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Healius Ltd. engages in the provision of healthcare technology solutions. The company is headquartered in Sydney, New South Wales. The Company’s specialized pathology businesses deliver healthcare services across Australia. The company provides pathology services, including specialty pathology and clinical trials. The company offers its medical laboratory and pathology services through a variety of specialty brands. The company provides medical laboratory and pathology services across key diagnostic activities. These include anatomical pathology (histopathology and cytology), clinical pathology (biochemistry, hematology, immunology and microbiology), genomic diagnostics and veterinary pathology. Its brands include QML, Laverty, Dorevitch, Western Diagnostic Pathology, TML, Agilex Biolabs, and Abbott Pathology, among others. These brands operate in Queensland, New South Wales (including the Australian Capital Territory), Victoria, Western Australia and Northern Territory, Tasmania, and South Australia. The company provides specialty diagnostic services to consumers and their referring practitioners.
📈 Performance
Price History
-79.63%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
35.76%
💰 Annual Dividend Earnings Per $1,000 invested**
$357.58
💰 Most Recent Dividend Franked Percentage Estimate
100.00%
💰 Average Dividend Franked Percentage Estimate
96.43 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of HLS, your last dividend payment(s) would have been:
$ 3,831.17
on Fri May 23 2025
$ 235.48
on Wed Sep 21 2022
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2025
$0.00
0.00%
2024
$0.00
0.00%
2023
$0.00
0.00%
2022
$0.16
100.00%
2021
$0.13
100.00%
2020
$0.03
Infinity%
2019
$0.07
100.00%
2018
$0.11
100.00%
2017
$0.11
100.00%
2016
$0.12
50.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🍃 Environmental, Social and Governance scores ℹ️
🌳
Environmental Score
99
A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution
⚖️
Governance Score
39
An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.
🤓 Advanced information
Technical Info
💰 Price*
$0.74
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in HLS
31
📊 Total Capital Earnings
$78K
🔃 Average investment frequency
33 weeks
💵 Average investment amount
$3,916
⏰ Last time a customer invested in HLS
20 hours
HLS investor breakdown
💵 Income of investors
More than 200k
13%
150k - 200k
100k - 150k
8%
50k - 100k
41%
Less than 50k
33%
👶 Age of investors
18 - 25
26 - 34
13%
35 - 90
81%
🙋 Legal gender of investors
Female
35%
Male
65%
Pearlers who invest in HLS also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
9.69%
📊 Share price
$111.07 AUD
💸 FINANCIALS
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
🧱 MATERIALS
📈 HIGH PRICE GROWTH
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
17.98%
📊 Share price
$150.97 AUD
🤖 TECHNOLOGY
🌏 GLOBAL
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
7.83%
📊 Share price
$73.74 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
CSL
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
🙌 Performance (5Yr p.a)
-6.13%
📊 Share price
$199.00 AUD
🧬 BIOTECHNOLOGY
⚖️ HIGH GOVERNANCE
🕊️ SOCIALLY AWARE
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
23.43%
📊 Share price
$67.64 AUD
🇺🇸 UNITED STATES
📈 HIGH PRICE GROWTH
Want more shares? Try these...
🕊️
Social Score
55
An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.